ClinicalTrials.gg
RecruitingNCT04894643PARCUpdated Mar 20, 2026

Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer

An interventional study of Proton Ions and Nab-PACLitaxel in Pancreatic Cancer and Proton Therapy, sponsored by EBG MedAustron GmbH. Recruiting at 2 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by EBG MedAustron GmbH · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Sep 2020, registered May 2021).
  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms — 22 open to participants now, 33 under way, 4 of them phase 3. Albumin-Bound Paclitaxel · Pancreatic Neoplasms.

Planned enrollment
113th of 130
10 · median 47
Started
2020
with 9 others
No phase
3 of 130
1 open now
Primary completion
2026-12
later than 14 of 32 live
Registered
101st of 130
by date

Among the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, this one is the 113th largest by planned enrollment, is one of 10 that started in 2020, is one of 3 with no phase, reaches primary completion later than 14 of the 32 other live ones, and was the 101st registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

22 of the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

This is an interventional, single arm, open-label, feasibility trial with gemcitabine and nab-paclitaxel, followed by concomitant proton therapy and capecitabine, followed by re-evaluation and surgery (when feasible) for patients with borderline resectable pancreatic cancer.

Read the detailed description

This is an interventional, single arm, open label, feasibility trial of preoperative chemotherapy + concomitant chemo-proton therapy followed by surgery (when feasible) for patients with borderline resectable pancreatic cancer. Aim of this study is to test referral and enrollment procedures as well as technical feasibility. Proton therapy will be delivered in MedAustron, which is a stand alone facility. Pancreatic cancer patients are typically complex cases that require multidisciplinary care. Moreover delivery of high dose of proton therapy to large volumes including the upper abdomen lymphnodes and pancreatic neural plexus is technically challenging, therefore a feasibility study is deemed necessary. Following this study, a larger study will be performed aiming to confirm the ability of preoperative chemotherapy + concomitant chemo-proton therapy to improve resectability and ultimately outcome of borderline resectable pancreatic cancer without increase in toxicity.

03

Conditions studied

  • Pancreatic Cancer
  • Proton Therapy

Keywords

  • Proton therapy combined with chemotherapy
  • Borderline Resectable Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with or cytologically confirmed diagnosis of pancreatic cancer
  • Diagnosis of borderline resectable cancer according to the international consensus definition 2017.
  • Negative staging for distant
  • Blood test within the following limits > 1,500 cells/mm³, count > 100,000 cells/mm³, (AST) and Alanine Aminotransferase (ALT) \< 2.5 times the , total \< 2.5 times the upper limit of normal if patient had recent biliary stenting, total bilirubin \< 1.5 times the upper limit of normal if no biliary stenting was done, serum creatinine within normal range (0.6-1.5 mg/dl) with a > 30 ml/min (as estimated by Cockroft Gault equation)
  • Age > 18 years
  • index ≥ 70
  • No tumor infiltration of stomach or duodenum
  • The patient is informed of the diagnosis and is able to give (Ability of subject to understand character and individual consequences of the study protocol)
  • Women of fertile age must have adequate conception prevention measures and must not breast feed
  • Signed Informed Consent (must be available before study inclusion)

Exclusion criteria

Exclusion Criteria:

  • Non-exocrine tumors
  • Major medical or psychiatric comorbidities that contraindicate radiation therapy, chemotherapy or surgery
  • Presence of distant
  • Pregnancy or unwilling to do adequate conception prevention
  • Lactating and unwilling to discontinue lactation
  • Men of not willing to use effective means of
  • Known allergic/ reaction to any of the components of study treatments
  • Previous diagnosis of another neoplasm with worse prognosis as compared with the one in this study
  • Metallic prosthesis or other condition that prevent an adequate imaging for target volume definition
  • Loco-regional conditions that contraindicate radiotherapy e.g. active infections in the area
  • Previous abdominal radiotherapy
  • Prior systemic treatment for pancreatic cancer
  • Hypersensitivity to PACLitaxel, albumin, gemcitabine or to any of the of the chemotherapy
  • Severe hepatic impairment
  • Baseline \< 1.5 x 10\^9/L
  • Baseline Grade ≥ 2 sensory or motor neuropathy
  • Patient refusal
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Other
    Preoperative, proton- radiotherapy combined with chemotherapy

    Patients treated with three cycles of chemotherapy with Nab-PACLitaxel (Abraxane®) (125 mg/m² on day 1, 8, 15; powder for making a infusion solution) and Gemcitabine (1000 mg/m² on day 1, 8, 15; powder for making a infusion solution), followed by concomitant chemotherapy with capecitabine (1.660ml/m² on 5 days per week during the radiation therapy) and proton-therapy (with simultaneous integrated boost (SIB) 50.4 Gy Relative Biological Effectiveness (RBE) and 60.2 Gy (RBE) in 28 fractions of 1.8 Gy (RBE) and 2.15 Gy (RBE) 5 days per week), followed by re-evaluation and surgery

    Radiation: Proton Ions · Drug: Nab-PACLitaxel · Drug: Gemcitabine · Drug: Capecitabine · Procedure: Surgical resection of the pancreas (when feasible)

Interventions

  • RadiationProton Ions

    According to the radiation plan (between 50.4 and a maximum of 60.2 Gy) after Chemotherapy with Nab-PACLitaxel (Abraxane®) + Gemcitabine and concomitant to Capecitabine.

  • Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy. It will be administered as intra venous infusion over 30 minutes.

    Also known as: Abraxane®

  • Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy. Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel.

  • Concomitant to proton-radiotherapy (on the same days, within week 14-19)

  • ProcedureSurgical resection of the pancreas (when feasible)

    Pre surgical re-evaluation will be performed at week 21 after enrollment. Patients fulfilling surgery-entry criteria, which consist of no distant metastasis, no massive ascites, no massive pleural effusion, no serious infection, no serious, unresolved chemoradiotherapy related, adverse events and adequate organ system function, will undergo surgery on week 22 (± 1 week). This should be performed via laparotomy.

06

What researchers measure

Primary outcomes

  1. Toxicity - Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Incidence of CTCAE version 5.0 Grade 4 non hematological toxicity from enrollment to six months after surgery

    Time frame: from enrollment to six months after surgery

  2. Perioperative Mortality and Complications

    Incidence of 90-days-perioperative mortality and incidence of Clavien Dindo Grade III complication rate during hospitalization

    Time frame: 90 days postoperatively

Secondary outcomes

  1. Toxicity - CTCAE v5.0

    CTCAE V5.0 toxicity from enrollment to six month after surgery

    Time frame: from enrollment to six months after surgery

  2. Tumor recurrence

    local and loco-regional (i.e. in-field) tumor recurrence

    Time frame: 260 weeks after therapy

  3. Progression free survival

    loco-regional progression-free survival

    Time frame: 260 weeks after therapy

  4. Overall survival

    Overall survival

    Time frame: 282 weeks

  5. Pathologic tumor response

    Assessment of pathologic tumor response to pre-operative combined proton- chemotherapy (R0 margin and N0, degree of tumor cell necrosis in the resected tumor specimen)

    Time frame: 260 weeks

  6. Radiologic response

    Assessment of radiologic response of pre-operative chemoradiotherapy. Response to preoperative treatment will be scored with the Japan Pancreas Society (JPS) classification which is a synthesis from the Evans and College of American Pathologists classification (Grade 1: poor or no response to Grade 4: complete response)

    Time frame: 263 weeks after proton therapy

  7. Quality of Life questionnaire: Functional Assessment of Cancer Therapy - Hepatobiliary (FACT-Hep)

    Patient reported Quality of Life (for assessing disease-related symptoms and health-related quality of life). The higher the score the better the Quality of Life.

    Time frame: 282 weeks

  8. Quality of Life questionnaire: European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-30)

    Questionnaire developed to assess the quality of life of cancer patients. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / quality of life (QoL) represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: 282 weeks

  9. Quality of Life questionnaire: Brief Pain Inventory

    The Brief Pain Inventory (BPI) is a measurement tool for assessing clinical pain.The interference items were now presented with 0-10 scales, with 0=no interference and 10=interferes completely.

    Time frame: 282 weeks

07

Study locations

2 of 2 sites recruiting
  • EBG MedAustron GmbH
    Wiener Neustadt, Lower Austria 2700, Austria
    Recruiting
  • Department of Surgery, LK Wiener Neustadt
    Wiener Neustadt, 2700, Austria
    Recruiting
    • Friedrich Längle, Prim., Univ. Doz., M.D. · Contactfriedrich.laengle@wienerneustadt.lknoe.at · +43 2622 9004
    • Friedrich Längle, Prim., Univ. Doz., M.D. · Principal investigator
    • Birgit Grünberger, Prim., Priv. Doz., M.D. · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Dec 2026, 75 months after the start.

Of 430 interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 75 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2021
First posted
May 20, 2021
StartActual
Sep 14, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04894643
Lead sponsor
EBG MedAustron GmbH
Collaborators
Landesklinkum Wiener Neustadt
Responsible party
Sponsor
First posted
May 20, 2021
Start date
Sep 14, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 20, 2026

Study contacts

Piero Fossati, M.D.
Contact
piero.fossati@medaustron.at
+43 664 80878 ext. 408
Piero Fossati, M.D.
principal investigator · EBG MedAustron GmbH
Friedrich Längle, Prim., Univ. Doz., M.D.
principal investigator · LK Wiener Neustadt, Department of Surgery

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albumin-Bound Paclitaxel · Gemcitabine · Capecitabine

Start the discussion